

PrCAMZYOS® (mavacamten capsules)

Patient Guide

Date of Internal Approval: June-2025

Local Approval Number: 3500-CA-2500010E




This material was developed by Bristol Myers Squibb as part of the risk minimization plan for CAMZYOS.

This material is not intended for promotional use.

INTRODUCTION

You have been provided with this **Patient Guide** because you have been prescribed CAMZYOS. CAMZYOS is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (also known as oHCM).



This **Patient Guide** contains a **Patient Card**. **Carry this Patient Card with you at all times.** Tell any healthcare professional who sees you that you are taking CAMZYOS. The **Patient Card** contains information on the main risks of CAMZYOS and contact details of your prescriber.

Please ensure that you read the Patient Medication Information for this medicine, which gives more information about CAMZYOS. If you have any further questions, talk to your prescriber, doctor or pharmacist.

WHAT IS SYMPTOMATIC OBSTRUCTIVE HCM?

Hypertrophic cardiomyopathy, or HCM, causes the heart muscle wall to thicken and stiffen, making it harder for the heart to fill with blood. In some patients with HCM, the heart muscle becomes so thick that it blocks or reduces blood flow from the heart to the rest of the body.

WHAT ARE ECHOCARDIOGRAMS AND WHY ARE THEY IMPORTANT?

Regular echocardiograms (also known as ECHOs) will help your doctor evaluate how CAMZYOS affects your heart. An ECHO is a test that uses sound waves to create pictures of the heart. These tests allow your doctor to see how your heart is responding to treatment, if your dose requires modification and to monitor for side effects. Based on the ECHO results, your doctor may increase, decrease or maintain your dose of CAMZYOS or pause or stop your treatment. Your first ECHO will be performed before starting CAMZYOS. Follow-up ECHOs will be 4, 8 and 12 weeks after your first dose of CAMZYOS and then every 12 weeks after an individual maintenance dose has been achieved. After that, assessment should be done at least every 6 months.

You will also need to have ECHOs as instructed by your doctor if your dose of CAMZYOS is changed or if the dose of another medicine you are taking is changed. This will mean that you will have a follow-up ECHO 4 and 8 weeks after your dose is changed and then return to the regular ECHO schedule of every 12 weeks until an individual maintenance dose has been achieved. After that, ECHO assessment should be done at least every 6 months.



It is important to schedule and attend ECHOs as instructed by your prescriber. Set reminders on your phone or calendar to help you remember the date and time of your ECHOs.



IMPORTANT SAFETY INFORMATION

Serious side effects and risks associated with the treatment with CAMZYOS are:

- Heart failure due to systolic dysfunction, a condition where the heart cannot pump enough blood to the body
- Heart failure due to interactions with certain medicines and herbal supplements
- Embryo-fetal toxicity (toxicity to an unborn baby)

Other possible side effects related to CAMZYOS are outlined in the Patient Medication Information, available at: https://www.bms.com/assets/bms/ca/documents/productinformation/CAMZYOS_EN_PMI.pdf

CAMZYOS and heart failure

Heart failure due to systolic dysfunction is a serious and sometimes fatal condition.

Tell your prescriber or doctor; or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, rapid weight gain, a racing heart (palpitations) or leg swelling.

Tell your prescriber or doctor of any new or existing medical condition(s) you experience before and during treatment with CAMZYOS. Certain conditions, such as infections or atrial fibrillation (irregular and rapid heartbeat), may impact your treatment with CAMZYOS.



IMPORTANT SAFETY INFORMATION (continued)

CAMZYOS and drug interactions

Some products, including prescription or over-the-counter medicines, vitamins, some herbal supplements and grapefruit juice can affect the levels of CAMZYOS in your body and may increase the risk of heart failure due to systolic dysfunction.

Talk about any health conditions or problems you may have, including if you are taking any prescription, over-the-counter medicines, vitamins, herbal supplements or grapefruit juice, even if you do not take them every day. **Do not** start taking, stop taking or change the dose of any of your medicines or herbal supplements without talking to your prescriber, doctor or pharmacist.

Some examples of medicines and products that may affect how much CAMZYOS is in your body are shown in **Table 1**. Please note, these examples are a guide and are not considered a comprehensive list of all possible medicines that may fit this category. Intermittent use of products that might affect the levels of CAMZYOS in your body, including prescription and over-the-counter medicines, vitamins, herbal supplements and grapefruit juice, is not recommended.

Table 1: Examples of medicines and products that may affect CAMZYOS

Medicines/products	Condition treated
Omeprazole, esomeprazole	Gastric ulcers and acid reflux
Clarithromycin, rifampicin	Bacterial infections
Verapamil, diltiazem	Heart conditions
Fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole	Fungal infections
Fluoxetine, fluvoxamine	Depression
Ritonavir, cobicistat	Human immunodeficiency virus (HIV)
Grapefruit juice	



IMPORTANT SAFETY INFORMATION (continued)

CAMZYOS and embryo-fetal toxicity (toxicity to unborn baby)

CAMZYOS must not be taken if you are pregnant or if you are of childbearing potential and are not using a highly effective method of contraception (birth control) as CAMZYOS may cause harm to an unborn baby.

If you are able to get pregnant, you will need a confirmed negative pregnancy test before you start taking CAMZYOS. You must use a highly effective method of contraception throughout treatment and for at least 4 months after your last dose of CAMZYOS. You should discuss with your doctor which method(s) of contraception is/are the most suitable for you.

Talk to your doctor if you are considering becoming pregnant. If you suspect you may become pregnant or are pregnant while receiving CAMZYOS, tell your prescriber or doctor **immediately**. Your prescriber or doctor will discuss your treatment options with you.



WHEN SHOULD I SEEK MEDICAL ATTENTION?

Tell any healthcare professional who sees you if any side effects occur while taking CAMZYOS, even those not discussed in this **Patient Guide**. Possible side effects and details of how to report them are also provided in the package leaflet. Reporting side effects to Health Canada helps collect additional safety information on this medicine.

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting <http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php> for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Tell your prescriber or doctor or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, rapid weight gain, a racing heart (palpitations) or leg swelling.



FURTHER INFORMATION

If you have any questions or concerns regarding CAMZYOS, please discuss them with your prescriber, doctor, pharmacist or any member of your healthcare team.

For more information or to obtain a copy of this document, please contact Medical Information by calling 1-866-463-6267.

Pr**CAMZYOS®** (mavacamten capsules)

PATIENT CARD



Patient instructions: Carry this card with you at all times.
Tell any healthcare professional who sees you that you are taking CAMZYOS.

This material was developed by Bristol Myers Squibb as part of the risk minimization plan for CAMZYOS.

This material is not intended for promotional use.

Date of internal approval: June 2025

3500-CA-2500010E



NOTES

[illegible]

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

